Loading…
Aldeyra Therapeutics, Inc. is projected to rise to $2.82 by 2027, a +36% move from its current price of $2.07. ALDX is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 14 | $1.97 | $2.07 | $2.18 | +0.08% |
| Jul 15 | $1.93 | $2.07 | $2.23 | +0.16% |
| Jul 16 | $1.90 | $2.07 | $2.27 | +0.24% |
| Jul 17 | $1.87 | $2.08 | $2.30 | +0.31% |
| Jul 18 | $1.85 | $2.08 | $2.33 | +0.39% |
| Jul 19 | $1.83 | $2.08 | $2.36 | +0.47% |
| Jul 20 | $1.81 | $2.08 | $2.39 | +0.55% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.81 | $2.08 | $2.39 | +0.55% |
| Week 2 | $1.72 | $2.09 | $2.54 | +1.10% |
| Week 3 | $1.66 | $2.10 | $2.67 | +1.66% |
| Week 4 | $1.61 | $2.12 | $2.78 | +2.22% |
| Week 5 | $1.57 | $2.13 | $2.89 | +2.78% |
| Week 6 | $1.53 | $2.14 | $2.99 | +3.35% |
| Week 7 | $1.50 | $2.15 | $3.09 | +3.92% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Aldeyra Therapeutics, Inc. is a biotechnology company that discovers and develops therapies designed to treat immune-mediated diseases. It operates in the Healthcare sector and focuses on RASP-modulating approaches through its lead and subsidiary programs.
Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis. The company also develops ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa, and ADX-629, an orally administered RASP modulator that is in Phase 2 clinical trials for the treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication.
The company also develops preclinical RASP platforms, including ADX 248, ADX 246, and other novel RASP modulators. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.
Aldeyra Therapeutics, Inc. (ALDX) is a biotechnology company with a current price of $2.07 and a market capitalization of $124.86M. It is ranked 4073 in market capitalization among listed assets.
The stock’s 30-day range spans from $1.47 to $2.91, with a 50-day moving average of $1.81 and a 200-day moving average of $3.74. The forecast section shows a long-run upside, with 2026 avg price of $2.07 and a 2050 avg price of $29.94, and a 2050 max of $68.87 and a 2050 min of $13.47. The implied ROI grows from 0 in 2026 to 1346.6 in 2050, with sentiment turning bullish in later years.
A major floor 40.1% below — a decisive break under it would weaken the trend.
The nearest floor, 21.3% below — buyers have tended to step in here.
The nearest ceiling, 17.4% above — a clean break opens room to run.
A major ceiling 154.1% above — clearing it would confirm fresh momentum.
Key ALDX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ALDX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $2.20 | Sell | $2.17 | Sell |
| MA 10 | $2.17 | Sell | $2.14 | Sell |
| MA 20 | $2.01 | Buy | $2.05 | Buy |
| MA 50 | $1.81 | Buy | $2.02 | Buy |
| MA 100 | $2.42 | Sell | $2.47 | Sell |
| MA 200 | $3.74 | Sell | $3.20 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 52.52 | Neutral |
| Stoch RSI (14) | 11.86 | Buy |
| CCI (20) | 20.55 | Neutral |
| Williams %R (14) | -57.14 | Info |
| MACD (12,26,9) | 0.01 | Buy |
| ROC (12) | 2.48 | Buy |
| Bollinger %B (20,2) | 0.57 | Neutral |
| Stochastic %K (14) | 42.86 | Neutral |
| TRIX (15) | 0.92 | Buy |
| Awesome (5,34) | 0.32 | Buy |
| Ultimate (7,14,28) | 50.10 | Neutral |
| Momentum (10) | 0.27 | Buy |
| Aroon Osc (25) | 68.00 | Buy |
| Hull MA (9) | 2.18 | Sell |
| ADX (14) | 17.62 | Neutral |
| ATR (14) | 0.11 | Info |
Technical snapshot for the next 30 days shows sentiment labeled as BULLISH and RSI14 at 50. The SMA50 is $1.81 and the SMA200 is $3.74. Support is at $1.63 and resistance at $2.43. The 30-day price range is $1.47 to $2.91, reflecting a relatively tight near-term corridor. Annualized volatility is 100%.
Overall, near-term dynamics suggest a balanced to bullish tilt within the established range, with key levels to watch around the support and resistance marks.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.24 | $2.07 | $3.27 | 0% | Neutral | |
| $2.06 | $2.82 | $4.18 | +36% | Bullish | |
| $2.03 | $2.94 | $4.64 | +42% | Bullish | |
| $2.16 | $3.30 | $5.45 | +59% | Bullish | |
| $2.19 | $3.50 | $6.02 | +69% | Bullish | |
| $2.72 | $4.54 | $8.07 | +119% | Bullish | |
| $3.46 | $6.02 | $11.03 | +191% | Bullish | |
| $3.84 | $6.93 | $13.06 | +235% | Bullish | |
| $4.27 | $8.01 | $15.46 | +287% | Bullish | |
| $3.64 | $7.08 | $13.98 | +242% | Bullish | |
| $6.42 | $14.27 | $30.91 | +589% | Bullish | |
| $13.47 | $29.93 | $68.84 | +13.5x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $1.24 | $2.07 | $2.61 | +0.00% |
| August 2026 | $1.77 | $2.14 | $2.69 | +3.18% |
| September 2026 | $1.81 | $2.22 | $2.86 | +4.11% |
| October 2026 | $1.96 | $2.44 | $3.18 | +9.57% |
| November 2026 | $1.99 | $2.50 | $3.31 | +2.45% |
| December 2026 | $1.93 | $2.44 | $3.27 | -2.28% |
Click any year to see its month-by-month ALDX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, ALDX could reach as high as $3.27, with a base case around $2.07 and support toward $1.24 — roughly 0% from $2.07. Price action looks broadly range-bound.
Expect ALDX to range from $2.06 to $4.18 through 2027. The $2.82 average target implies a +36% move from current prices. That is up +36% on the projected 2026 average. Buyers look set to stay in control over this stretch.
The ALDX price prediction for 2028 points to an average of $2.94 (low $2.03, high $4.64) — a potential gain of +42% on today's $2.07. Momentum favours further upside here.
In 2029, ALDX is projected to trade between $2.16 and $5.45, averaging $3.30 — a potential gain of +59% from today's $2.07. That is up +12% on the projected 2028 average. Buyers look set to stay in control over this stretch.
Aldeyra Therapeutics, Inc.'s 2030 outlook centres on $3.50, within a $2.19 to $6.02 range. That is up +6% on the projected 2029 average. That marks a +69% change versus current levels. Momentum favours further upside here.
By 2031, ALDX could reach as high as $8.07, with a base case around $4.54 and support toward $2.72 — roughly +119% from $2.07. Buyers look set to stay in control over this stretch.
Expect ALDX to range from $3.46 to $11.03 through 2032. The $6.02 average target implies a +191% move from current prices. That is up +33% on the projected 2031 average. Momentum favours further upside here.
The ALDX price prediction for 2033 points to an average of $6.93 (low $3.84, high $13.06) — a potential gain of +235% on today's $2.07. Buyers look set to stay in control over this stretch.
In 2034, ALDX is projected to trade between $4.27 and $15.46, averaging $8.01 — a potential gain of +287% from today's $2.07. That is up +16% on the projected 2033 average. Momentum favours further upside here.
Aldeyra Therapeutics, Inc.'s 2035 outlook centres on $7.08, within a $3.64 to $13.98 range. That is -12% versus the projected 2034 average. That marks a +242% change versus current levels. Buyers look set to stay in control over this stretch.
By 2040, ALDX could reach as high as $30.91, with a base case around $14.27 and support toward $6.42 — roughly +589% from $2.07. Momentum favours further upside here.
Expect ALDX to range from $13.47 to $68.84 through 2050. The $29.93 average target implies a +13.5x move from current prices. That is up +110% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in ALDX today (≈ 483.091787 ALDX) could be worth
$14,459.9
+$13,459.9 (+1346%) by 2050 · US Dollar
Based on the average projected ALDX price of $29.93 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ALDXwould be worth at today's price.
$1,000 invested in ALDX on Jul 10, 2025 (≈ 208.333325 ALDX) would be worth
$431.25
-$568.75 (-56.9%) today · 0.43× · US Dollar
Based on a ALDX entry price of $4.8 vs. today's $2.07.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $2.27 | $911.89 | -8.8% |
| 1 month ago | $1.69 | $1,224.85 | +22.5% |
| 3 months ago | $1.78 | $1,162.92 | +16.3% |
| 6 months ago | $4.13 | $501.21 | -49.9% |
| 1 year ago | $4.8 | $431.25 | -56.9% |
| All time (5.0y) ago | $9.82 | $210.79 | -78.9% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ALDX forecast.
Our base-case forecast reaches $4.10 around 2031.
Implied market cap at $4.10: $247.32M
The multi-year forecast depicts sustained upside, with 2027 avg at $2.83 and ROI 36.5, followed by 2028 avg at $2.94 and ROI 42, 2029 avg at $3.30 and ROI 59.3, and 2030 avg at $3.51 and ROI 69.5. The outlook remains bullish through 2031–2035, with 2031 avg $4.53, 2032 $6.02, 2033 $6.95, 2034 $8.00, and 2035 $7.08, all carrying bullish sentiment.
Longer-range projections show 2040 avg $14.25 and ROI 588.4, and 2050 avg $29.94 with ROI 1346.6 and max $68.87. These figures illustrate meaningful upside potential over the coming decades, though they are estimates and not guarantees. The projected path combines rising averages with expanding ROI as time advances.
Tap a question to reveal the answer.
In 2030, the forecast shows an average price of $3.51, with a min of $2.19 and a max of $6.03, implying an ROI of 69.5 and a bullish sentiment.
The forecast turns bullish from 2027 onward, with 2027 avg $2.83 (ROI 36.5), 2028 avg $2.94 (ROI 42), 2029 avg $3.30 (ROI 59.3), and 2030 avg $3.51 (ROI 69.5), culminating in 2050 avg $29.94 (ROI 1346.6) and a bullish overall outlook.
Yes, the forecast maximum by 2050 is $68.87, which exceeds $50, supported by a 2050 max of $68.87 and a 2050 avg of $29.94 with ROI 1346.6.
Current price is $2.07 and the market capitalization is $124.86M.
For 2040, the average price is $14.25, the min is $6.41, the max is $30.87, and the ROI is 588.4 with bullish sentiment.
Aldeyra Therapeutics, Inc. Community Discussion
0Share your Aldeyra Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.